Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 16/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CALML3 | P27482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13298923 | 0.90 | MAOA (0.82) | MAOAKCNH2CYP3A4CYP2D6CALML3 | |
| SCHEMBL3326714 | 0.88 | MAOA (0.70) | MAOAKCNH2CYP3A4CYP2D6MAOB | |
| SCHEMBL3325391 | 0.87 | MAOA (0.69) | MAOAKCNH2CYP3A4CYP2D6MAOB | |
| SCHEMBL4017518 | 0.86 | MAOA (0.68) | MAOAKCNH2CYP3A4CYP2D6MAOB | |
| SCHEMBL5639387 | 0.85 | MAOA (0.67) | MAOAKCNH2CYP3A4CYP2D6MAOB | |
| SCHEMBL3327186 | 0.85 | MAOA (0.72) | MAOACYP3A4CYP2D6MAOBCALML3 | |
| SCHEMBL3367952 | 0.84 | MAOA (0.66) | MAOAKCNH2CYP3A4CYP2D6MAOB | |
| SCHEMBL5639096 | 0.84 | MAOA (0.65) | MAOAKCNH2CYP3A4CYP2D6MAOB | |
| SCHEMBL5931081 | 0.83 | MAOA (0.65) | MAOAKCNH2CYP3A4CYP2D6MAOB | |
| SCHEMBL3326548 | 0.83 | MAOA (0.65) | MAOAKCNH2CYP3A4CYP2D6MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2256120-A1 | Oxazolidinone-quinolone hybrids as antibacterial compounds | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-20100222302-A1 | Novel Antibacterial Compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-02 | — | — | US | disclosed |
| EP-1931684-A2 | OXAZOLIDINONE-QUINOLONE HYBRIDS AS ANTIBACTERIAL COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007017828-A2 | OXAZOLIDINONE-QUINOLONE HYBRIDS AS ANTIBACTERIAL COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222302-A1 | Novel Antibacterial Compounds | ODC1, AOC1, OGFOD1 | MAOA 1464/4885KCNH2 394/4885CYP3A4 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.